

B10 status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, and other disorders of bone metabolism, or for accelerating bone growth or repair, which composition is characterized by the inclusion of a peptide (SEQ ID NO: 7).

B11 3. (Once Amended) The pharmaceutical composition according to Claim 1, wherein the peptide (SEQ ID NO: 6) is

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

B12 5. (Once Amended) A method of preparing a pharmaceutical composition for the treatment of osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, which method comprises the mixing of a peptide according to the sequence (SEQ ID NO: 6).

7. (Once Amended) The method of Claim 5, wherein the peptide is
pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

B13 8. (Once Amended) A method of treatment of an individual suffering from osteoporosis, including age-related osteoporosis and osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis, or another disorder of bone growth, or at risk of so suffering, which comprises the administration to said individual of a therapeutically effective amount of a pharmaceutical composition which includes a peptide according to the sequence (SEQ ID NO: 7).

10. (Once Amended) The method of Claim 8, wherein the peptide is (SEQ ID NO: 6)
pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH₂ (6)

B14 11. (Once Amended) A new use for a peptide according to the sequence (SEQ ID NO: 7)

pyroGlu-His-Trp-Ser-Xaa¹-Gly- Xaa²- Xaa³-Pro-Gly-NH₂ (7)